Abbott (ABT) stock price, revenue, and financials

Abbott market cap is $214.6 b, and annual revenue was $34.61 b in FY 2020

$214.6 B

ABT Mkt cap, 23-Jul-2021

$10.5 B

Abbott Revenue Q1, 2021
Abbott Gross profit (Q1, 2021)6.1 B
Abbott Gross profit margin (Q1, 2021), %57.9%
Abbott Net income (Q1, 2021)1.8 B
Abbott EBIT (Q1, 2021)2.1 B
Abbott Cash, 31-Mar-20218.1 B
Abbott EV225 B
Get notified regarding key financial metrics and revenue changes at AbbottLearn more
Banner background

Abbott Revenue

Abbott revenue was $34.61 b in FY, 2020 which is a 8.5% year over year increase from the previous period.

Embed Graph

Abbott Revenue Breakdown

Embed Graph

Abbott revenue breakdown by business segment: 12.4% from Established Pharmaceuticals, 22.1% from Nutritionals, 31.2% from Diagnostics, 34.1% from Medical Devices and 0.2% from Other

Abbott revenue breakdown by geographic segment: 37.6% from United States and 62.4% from International

Abbott Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

30.6b31.9b34.6b

Revenue growth, %

12%4%8%

Cost of goods sold

12.7b13.2b15.0b

Gross profit

17.9b18.7b19.6b

Gross profit Margin, %

58%59%57%

R&D expense

2.3b2.4b2.4b

General and administrative expense

9.7b9.8b9.7b

Operating expense total

14.2b14.1b14.2b

Depreciation and amortization

2.2b1.9b2.1b

EBIT

3.7b4.5b5.4b

EBIT margin, %

12%14%15%

Interest expense

826.0m670.0m546.0m

Interest income

105.0m94.0m46.0m

Pre tax profit

2.9b4.1b5.0b

Income tax expense

539.0m390.0m497.0m

Net Income

2.4b3.7b4.5b

EPS

1.32.12.5

Abbott Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

3.8b3.9b6.8b

Accounts Receivable

5.2b5.4b6.4b

Inventories

3.8b4.3b5.0b

Current Assets

14.6b15.7b20.4b

PP&E

7.6b8.0b9.0b

Goodwill

23.3b23.2m23.7b

Total Assets

67.2b67.9b72.5b

Accounts Payable

3.0b3.3b3.9b

Dividends Payable

563.0m635.0m798.0m

Short-term debt

207.0m1.5b220.0m

Current Liabilities

9.0b10.9b11.9b

Long-term debt

19.4b16.7b18.5b

Total Debt

19.6b18.1b18.7b

Common Stock

23.5b23.9b24.1b

Retained Earnings

24.6b25.8b27.6b

Total Equity

30.7b31.3b33.0b

Debt to Equity Ratio

0.6 x0.6 x0.6 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x

Financial Leverage

2.2 x2.2 x2.2 x

Abbott Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

2.4b3.7b4.5b

Depreciation and Amortization

3.3b3.0b3.3b

Accounts Receivable

(190.0m)(275.0m)(924.0m)

Inventories

(514.0m)(593.0m)(493.0m)

Accounts Payable

747.0m1.8b

Cash From Operating Activities

6.3b6.1b7.9b

Purchases of PP&E

(1.4b)(1.6b)(2.2b)

Cash From Investing Activities

(1.4b)(1.8b)(2.2b)

Short-term Borrowings

(26.0m)2.0m

Long-term Borrowings

(12.4b)(3.4b)(1.3b)

Dividends Paid

(2.0b)(2.3b)(2.6b)

Cash From Financing Activities

(10.4b)(4.3b)(2.8b)

Net Change in Cash

(5.6b)16.0m3.0b

Interest Paid

845.0m677.0m549.0m

Income Taxes Paid

740.0m930.0m970.0m

Abbott Ratios

USDFY, 2018

EV/EBIT

39.1 x

EV/CFO

22.7 x

Revenue/Employee

296.9k

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2.2 x

P/E Ratio

54.4

Abbott Operating Metrics

FY, 2018FY, 2019FY, 2020

Products

1.5 k1.5 k

New Product Launches

25

Manufacturing Sites

949293

Manufacturing Sites (Cardiovascular and Neuromodulation Products)

252727

Manufacturing Sites (Diagnostic Products)

232324

Manufacturing Sites (Established Pharmaceutical Products)

302828

Manufacturing Sites (Nutritional Products)

141414

Manufacturing Sites (Non-Reportable)

2

Abbott Human Capital

FY, 2020FY, 2019FY, 2018
Male, percent18.3%14.3%14.3%
Female (USA), percent15.7%11.5%11.5%
Male (USA), percent17.7%13.3%13.3%
Female (Management), percent13%9.8%9.5%
Male (Management), percent20.3%15.3%15.5%
Female, percent15%10.8%10.8%
Male (Management, USA), percent14.8%15%
Female (Management, USA), percent10.3%10%

Abbott Employee Rating

3.95662 votes
Culture & Values
3.6
Work/Life Balance
3.4
Senior Management
3.2
Salary & Benefits
3.8
Career Opportunities
3.4
Source